DiaMedica Therapeutics Inc
$ 8.23
-2.83%
26 Dec - close price
- Market Cap 428,597,000 USD
- Current Price $ 8.23
- High / Low $ 8.43 / 8.10
- Stock P/E N/A
- Book Value 0.99
- EPS -0.71
- Next Earning Report 2026-03-31
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.38 %
- ROE -0.64 %
- 52 Week High 10.42
- 52 Week Low 3.19
About
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Minneapolis, Minnesota, specializing in the development of innovative therapies targeting neurological and kidney diseases. The company’s lead candidate, DM199, is designed to enhance renal function in patients suffering from diabetic kidney disease, representing a vital solution for a significant unmet medical need. With a robust pipeline and a strategic focus on advancing its clinical programs, DiaMedica is poised to make substantial contributions to patient care and to capitalize on growth opportunities within the biopharmaceutical sector. Its commitment to delivering transformative treatments underscores its potential to impact healthcare significantly.
Analyst Target Price
$15.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-12 | 2025-05-06 | 2025-03-17 | 2024-11-11 | 2024-08-07 | 2024-05-08 | 2024-03-19 | 2023-11-13 | 2023-08-14 | 2023-05-15 | 2023-03-28 |
| Reported EPS | -0.17 | -0.18 | -0.18 | -0.18 | -0.15 | -0.13 | -0.14 | -0.14 | -0.12 | -0.16 | -0.2 | -0.14 |
| Estimated EPS | -0.17 | -0.19 | -0.18 | -0.1725 | -0.15 | -0.16 | -0.16 | -0.14 | -0.13 | -0.18 | -0.16 | -0.14 |
| Surprise | 0 | 0.01 | 0 | -0.0075 | 0 | 0.03 | 0.02 | 0 | 0.01 | 0.02 | -0.04 | 0 |
| Surprise Percentage | 0% | 5.2632% | 0% | -4.3478% | 0% | 18.75% | 12.5% | 0% | 7.6923% | 11.1111% | -25% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-31 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.1667 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DMAC
2025-12-20 04:09:09
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has received a "Moderate Buy" consensus rating from brokerages, with an average one-year target price of $12.33. This recommendation comes from seven analysts, including six "buy" ratings and one "sell." Recent insider and institutional activity shows accumulation of shares, with a major shareholder and several hedge funds increasing their positions.
2025-12-19 03:11:05
DiaMedica Therapeutics Inc. will conduct an additional non-clinical study for its DM199 treatment for preeclampsia, following a request from the FDA. The study results are expected by Q2 2026, and positive interim data from an ongoing Phase 2 trial show "encouraging safety and efficacy signals." Despite promising developments, three analysts have revised their earnings forecasts downwards for the company.
2025-12-18 15:10:01
DiaMedica Therapeutics (DMAC) has successfully concluded a pre-IND meeting with the FDA regarding a proposed study to evaluate DM199 for preeclampsia treatment. The FDA has requested an additional non-clinical study, with results anticipated by Q2 2026. Concurrently, a Phase 2 trial in South Africa is showing promising safety and efficacy outcomes for DM199 in over 30 women.
2025-12-18 14:10:01
DiaMedica Therapeutics announced a productive pre-IND meeting with the FDA for its DM199 preeclampsia program, which affirmed the need for an additional non-clinical study in rabbits, with results expected by Q2 2026. Interim data from a Phase 2 trial in South Africa show encouraging safety and efficacy signals, including blood pressure reductions and no placental transfer of DM199. The company is advancing DM199 development as a novel treatment for preeclampsia.
2025-12-18 14:10:01
DiaMedica Therapeutics updated investors on its DM199 preeclampsia program following an FDA pre-IND meeting. The FDA requested an additional non-clinical safety study of DM199 in a rabbit model, with results anticipated by Q2 2026. This regulatory step will influence the timing of the planned Phase 2 investigator-sponsored trial.
2025-12-18 14:10:01
DiaMedica Therapeutics Inc. (DMAC) announced updates on its DM199 preeclampsia program following an FDA meeting. The FDA requested an additional non-clinical study in rabbits, with results expected by Q2 2026 to support an IND submission. Promising safety data has been observed in a Phase 2 trial in South Africa, and DM199 shows no placental transfer, reducing potential fetal risk.
